Please assess the completion status of the following clinical trial:

Trial Title: Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants between the ages of \>15 months to \<12 years inclusive, at Visit 1 (Screen 1).~* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests lifestyle considerations and other study procedures.~* Completed the C4181005 Phase 2 study.~* Able to stand independently for height measurements (if ≥2 years of age at enrollment).~Exclusion Criteria:~* Presence of co-morbid conditions or circumstances that, in the opinion of the investigator, would affect interpretation of growth data or ability to complete the trial procedures.~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~* Presence of severe obesity (body mass index (BMI) \>95th percentile on Hoover-Fong BMI charts) \[Hoover-Fong et al, 2008\].~* Known closure of long bone growth plates (cessation of height growth).~* Body weight \>45 kg.~* History of hypersensitivity to study intervention or any excipients.~* History of any prior treatment with human growth hormone or related products (including insulin-like growth factor 1 \[IGF-1\]).~* History of receipt of any treatment that are known to potentially affect growth (including oral steroids \>5 days in the last 6 months, high dose inhaled corticosteroids (\>800 mcg/day beclometasone equivalent) and medication for attention deficit hyperactivity disorder).~* History of limb lengthening surgery (defined as distraction osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to extend bone length).~* Any limb lengthening/corrective orthopaedic surgery planned at any point during the trial period.~* Less than 6 months since fracture or surgical procedure of any bone determined from the screening visit date.~* Presence of any internal guided growth plates/devices.~* History of removal of internal guided growth plates/devices within less than 6 months.~* History of receipt of any other (except recifercept) investigational product for achondroplasia or that may affect growth/interpretation of growth parameters.~* History of receipt of an investigational drug (not for achondroplasia/growth affecting) within the last 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): Low Dose
- Medium Dose (Type: EXPERIMENTAL): Medium Dose
- High Dose (Type: EXPERIMENTAL): High Dose

Based on this trial design, predict the completion outcome and termination type (if applicable).